Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

Conference Call & Webcast Today at 2:00 p.m. CET

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Highlights

- Positive results of pivotal trial for Glybera(R) (AMT-011)

for Hyperlipoproteinemia type I

- European patent for treatment of Non-Alcoholic Steatotic

Hepatitis

- License for treatment of Duchenne Muscular Dystrophy from La

Sapienza University, Rome, Italy

- License for prevention of immune response against treatment of

Hemophilia B from 'TIGET", San Raffaele Telethon Gene Therapy Institute,

Milan, Italy

- Collaboration with St. Jude Children's Research Hospital,

Memphis, Tennessee, USA, including license for treatment of Hemophilia B

- GMP manufacturing development: License for raising yields of

production platform from NIH, Bethesda, USA

- Key financial figures in line with guidance

- Cash & cash equivalents of EUR 43.1 million at June 30, 2008

- Independent supervisory board with three new members bringing

extensive knowledge and experience.

Results comparison

AMT's key financial figures are in line with the guidance that the company has given for 2008. The operating loss increased to EUR 9.1 million for the six months ended June 30, 2008, from EUR 7.2 million for the same period in 2007. This difference is primarily due to the increase of research & development costs to EUR 5.8 million from EUR 3.8 million in the same period of 2007. This increase is particularly related to the development work on the company's lead product Glybera(R) (AMT-011) and increased staffing for this and other programs. General and administrative costs decreased slightly to EUR 3.3 million from EUR 3.5 million for the same period in 2007 due to lower share-based payments.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... 2013   Flexion Therapeutics , Inc. today announced ... to its management team as chief financial officer. ... management experience with biotechnology and medical device companies. ... financial officer for Novavax (NASDAQ: NVAX ) ... $250 million through a combination of investment funding and ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... Conference at 2:10 PM ET on Tuesday, December 13, ...
... Conn., Dec. 6, 2011 Biodel Inc. (Nasdaq: ... ended September 30, 2011. Fourth Quarter Operating ... 2011, the company: Selected a new lead ... a Phase 1 clinical trial; Extended an agreement with ...
... Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive ... be held on December 13-14, 2011 in New York.  ... scheduled to present an overview of the Company on ... A live webcast and subsequent archived replay ...
Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 6Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011 2
(Date:5/20/2013)... 2013) University of Minnesota Medical School researchers from ... with the University,s Brain Tumor Program, have developed a ... (MPNST) that allow them to discover new genes and ... research was published this week in the journal ... method, researchers in the lab of David Largaespada, Ph.D., ...
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/19/2013)... men and women of European descent inherit common foot ... deformities, including hammer or claw toe. Findings from the ... foot disorders in humansappear in Arthritis Care & ... of the American College of Rheumatology (ACR). , ... older adults have foot disorders which may limit mobility ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2
... (TEDs) are an increasingly common sight at airports ... carry them to evaluate suspicious packages. A new ... Standards and Technology (NIST) in cooperation with ASTM ... their performance and reliability. The new testing ...
... YORK (March 31, 2011) -- Researchers at Weill Cornell Medical ... to control fertility. They say their technique could possibly be ... hormones and their receptors are species-non-specific and are similar in ... an alternative to castration and adverse effects of hormone administration. ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
Cached Biology News:NIST, ASTM land a one-two punch to fight explosives terrorism 2Immune therapy can control fertility in mammals 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... TempliPhi 100 Amplification Kit, 100 reactions. ... sequencing in 4-6 h.Generate microgram quantities ... of starting material.Use amplified DNA directly ... from bacterial or M13 liquid cultures, ...
... Rack inserts fit into the ... allow you to greatly increase ... deepwell format plates at an ... from the shaker at once ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: